The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of ...

New Food and Drug Administration regulations went into effect on Sept ... to receive annual mammograms — X-ray imaging of ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

The Food and Drug Administration issued a rule in March 2023 that requires health care professionals to notify people if they have dense breasts. Studies have shown dense breast tissue can make it ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

Jazz Pharma's diversified drug portfolio drives revenue growth. Zanidatamab shows promise with potential FDA approval in late ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...

The Food and Drug Administration wants women with dense breasts to take special care of themselves. When they go for a ...